Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Hepion CRV431 featured on The Bio Report podcast

The Bio Report podcast featured Hepion Pharmaceuticals’ (NASDAQ:HEPA) CRV431 for the treatment of non-alcoholic steatohepatitis (NASH), and potentially, COVID-19. “We’ve kicked off our Phase 2 trial in NASH...

September 11, 2020

Markets

Lake Street starts Profound Medical at buy; PT $22 (U.S.)

Lake Street Capital Markets launched coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with a “buy” rating and $22 (U.S.) price target. The stock closed at $15.11 on Sept. 10. Profound develops, manufactures, and...

September 11, 2020

Developments

VBL Therapeutics enrolls first patients in Phase 2 metastatic colorectal cancer trial

VBL Therapeutics (NASDAQ:VBLT) enrolled the first two patients in its Phase 2 trial evaluating VB-111, in combination with nivolumab, for the treatment of metastatic colorectal cancer. VB-111 is an adenovirus that...

September 10, 2020

Developments

Satsuma Pharma STS101 fails Phase 3 migraine trial

Satsuma Pharmaceuticals (NASDAQ:STSA) reported disappointing topline results from its Phase 3 trial of STS101 for the acute treatment of migraine. STS101 is a drug-device combination of dihydroergotamine mesylate (DHE)...

September 10, 2020

Markets

Cowen starts DermTech at OP; PT $20

Cowen launched coverage of DermTech (NASDAQ:DMTK) with an “outperform” rating and $20 price target. The stock closed at $10.65 on Sept. 9. DermTech provides the only commercial-stage genomics-based non-invasive solution...

September 10, 2020

Markets

AGP ups Motus GI Holdings PT to $2.60 from $1.65

Alliance Global Partners raised its price target for Motus GI Holdings (NASDAQ:MOTS) to $2.60 from $1.65, “rolling our valuation multiple onto our newly introduced 2022 estimates and utilizing 50 million as our share...

September 9, 2020

Developments

Precision BioSciences gets FDA fast track designation for second allogeneic CAR-T cell therapy

Precision BioSciences’ (NASDAQ:DTIL) allogeneic chimeric antigen receptor (CAR-T) cell therapy, PBCAR269A, received FDA fast track designation for the treatment of relapsed/refractory multiple myeloma. PBCAR269A...

September 9, 2020

Markets

HCW reduces Corbus Pharma PT to $6 from $24

H.C. Wainwright slashed the price target for Corbus Pharmaceuticals (NASDAQ:CRBP) to $6 from $24 but maintained its “buy” rating after the company’s Phase 3 RESOLVE-1 trial of lenabasum in cutaneous systemic sclerosis...

September 9, 2020

Developments

Spero Therapeutics reports positive topline results from Phase 3 UTI and acute pyelonephritis trial

Spero Therapeutics (NASDAQ:SPRO) reported topline results from its Phase 3 ADAPT-PO trial evaluating tebipenem HBr for the treatment of complicated urinary tract infection (UTI) and acute pyelonephritis. Hospitalized...

September 8, 2020

Developments

Strongbridge Biopharma reports positive topline data from Phase 3 Cushing’s syndrome trial

Strongbridge Biopharma (NASDAQ:SBBP) reported topline data from its Phase 3 LOGICS trial evaluating RECORLEV for the treatment of endogenous Cushing’s syndrome. The study enrolled 44 patients to supplement the long-term...

September 8, 2020

Markets

Analysts cut Akebia Therapeutics PT but maintain buy ratings

Analysts for BTIG and H.C. Wainwright reduced their price targets for Akebia Therapeutics (NASDAQ:AKBA) to $6 and $10, respectively, but maintained their “buy” ratings after the company announced top-line results for...

September 4, 2020

Markets

HCW starts Surface Oncology at buy; PT $11

H.C. Wainwright launched coverage of Surface Oncology (NASDAQ:SURF) with a “buy” rating and $11 price target. The stock closed at $6.40 on Sept. 3. Surface is developing cancer therapies targeting checkpoints that...

September 4, 2020

Subscribe